Loading...
Freedom of Information (FOI) NHS Lothian | Our Organisation

Request and Response Register

NOTE: 100 recent requests are displayed below. Use search to find older requests.
Freedom of Information Request Reference: 10025
Date Received: 24/04/2025
Summary:
Please may I request, under FOI if necessary, a copy of your Standard Operating Procedures outlining clinical governance arrangements for when a mental health admissions divert pathway is operational for admissions across Edinburgh and surrounding areas.
Date of Response: 17/06/2025
View Response: 10025.pdf
Freedom of Information Request Reference: 10379
Date Received: 21/07/2025
Summary:
• How many times has the neonatal unit (or units if more than one) in the health board been unable to accept new admissions between 1 April 2024 and 31 March of this year? Please detail the recorded reason why. • How many times has the neonatal unit (or units if more than one) in the health board been unable to accept new admissions between 1 April 2023 and 31 March 2024? Please detail the recorded reason why.
Date of Response: 18/08/2025
View Response: 10379.pdf
Freedom of Information Request Reference: 10378
Date Received: 21/07/2025
Summary:
• On how many shifts/ occasions did staffing in neonatal units not meet the standard set by the British Association of Perinatal Medicine (BAPM) from 1 April 2024 to 31 March of this year? • On how many shifts/occasions did staffing in neonatal units not meet the standard set by the British Association of Perinatal Medicine (BAPM) from 1 April 2023 to 31 March 2024?
Date of Response: 22/08/2025
View Response: 10378.pdf
Freedom of Information Request Reference: 10377
Date Received: 21/07/2025
Summary:
1. Do clinicians in your trust have access to Intravenous Immunoglobulin (IVIg) for the treatment of myasthenia gravis (MG)? (Y/N) 2. If no, how do clinicians get access to IVIg when treating MG patients who require IVIg treatment 3. How many gMG patients received IVIg for MG treatment in the last year 4. Do clinicians in your trust have access to therapeutic plasma exchange (PLEX) for the treatment of myasthenia gravis (MG)? (Y/N) 5. If no, how do clinicians get access to PLEX when treating MG patients who require PLEX treatment? 6. How many gMG patients received PLEX for MG treatment in the last year
Date of Response: 21/08/2025
View Response: 10377.pdf
Freedom of Information Request Reference: 10376
Date Received: 21/07/2025
Summary:
I would like to request the following data for each of the financial years from 2014–15 to the most recent available, so I can compare the pre and post-refurbishment periods. 1. Bed Numbers • The number of designated haematology inpatient beds (both before and after the relocation to the refurbished unit). • The number of total inpatient beds at Western General Hospital over the same period. 2. Activity and Throughput • The total number of haematology inpatients treated per year. • The total number of haematology outpatient attendances (including day-case chemotherapy or other treatments managed via the day unit) per year. 3. Bed Occupancy and Outliers • The average monthly bed occupancy rate for haematology wards at Western General, expressed as a percentage. • The number of haematology inpatients who, during any point in their stay were boarded to non-haematology wards (i.e. “outliers”) due to capacity constraints, for each year. • If available, the average length of stay for haematology inpatients each year.
Date of Response: 22/08/2025
View Response: 10376.pdf
Freedom of Information Request Reference: 10375
Date Received: 21/07/2025
Summary:
Could you provide the number of GPs (WTE) who worked at the following GP practices each financial year from 2013 to 2024: 1.Braids Medical Practice - (Practice Code 70075) 2. Inch Park Surgery - (Practice Code 70921) 3. Bruntsfield Medical Practice - (Practice Code 70323) 4. Grange Medical Group - (Practice Code 70412) 5. Southern Medical Group - (Practice Code 70588) 6. Craiglockhart Medical Group - (Practice Code 70610) 7. Dr A Comiskey and Partners (Conan Doyle) - (Practice Code 70639) 8. Marchmont Medical practice - (Practice Code 70766) (as this practice is no longer active, please provide 2013-closure) 9. Morningside Medical Practice - (Practice Code 70790) 10. Barefoot Medical Practice - (Practice Code 70893) 11. Slateford Medical Practice - (Practice Code 70997) 12. Polwarth Medical Practice - (Practice Code 71011) 13. Hermitage Medical Practice - (Practice Code 71449) (as this practice was not active in 2013, please provide the figure from opening-2025) In addition, please provide the number of WTE GP's per 10,000 people in NHS Lothian for each financial year 2013-2024.
Date of Response: 19/08/2025
View Response: 10375.pdf
Freedom of Information Request Reference: 10374
Date Received: 21/07/2025
Summary:
Could you confirm whether the Burns Unit at St John's Hospital in Livingston is still operational? If it isn't could you provide an explanation as to why it isn't?
Date of Response: 14/08/2025
View Response: 10374.pdf
Freedom of Information Request Reference: 10373
Date Received: 21/07/2025
Summary:
Haem Questionnaires Haemophilia A Q1. In the past 12 months [latest 12 months available], how many patients have been diagnosed with the each of the following conditions in your Trust: Haemophilia A Acquired Haemophilia A (AHA) Congenital Haemophilia A with inhibitors (CHAwI) Q2. In the last twelve months[latest 12 months available], how many pts with Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta NovoSeven RT Obizur Cevenfacta Q3. In the last twelve months[latest 12 months available], how many patients with Acquired Haemophilia A, have been treated with each of the following products in your Trust: Factor Eight Inhibitor Bypass Activity (FEIBA) NovoSeven RT Obizur Cevenfacta Q4 In the last twelve months[latest 12 months available], how many pts with Congenital Haemophilia A with Inhibitors have been treated with each of the following products in your Trust? Factor Eight Inhibitor Bypass Activity (FEIBA) Hemlibra (standalone) Hemlibra in combination with NovoSeven RT Hemlibra in combination with Cevenfacta Hemlibra in combination with FEIBA Helimbra in combination with Factor VIII NovoSeven RT Obizur Cevenfacta Prothrombin Complex Concentrate (PCC) Q1. What is the total Prothrombin Complex Concentrate usage in International Units (IUs) for your Trust over the last 12 months [latest 12 months available] for each of the products below in your Trust? Prothromplex Beriplex Octaplex Q2: Can you share the Prothrombin Complex Concentrate usage in International Units for your Trust in the last 12 months [latest 12 months available] within each of the following departments, and which PCC is used? Prothromplex Beriplex Octaplex Departments Cardio-speciality General Medicine General surgery Haematology Emergency care Any other
Date of Response: 22/08/2025
View Response: 10373.pdf
Freedom of Information Request Reference: 10372
Date Received: 17/07/2025
Summary:
If a staff member encounters another staff member of the opposite sex in a single sex provision - such as changing room, hygiene area or toilet - would they be supported by Health board policy, via line management, to challenge and report this as a breach of The Workplace (Health, Safety and Welfare) Regulations 1992?
Date of Response: 14/08/2025
View Response: 10372.pdf
Freedom of Information Request Reference: 10371
Date Received: 17/07/2025
Summary:
I am requesting the following information regarding your Therapy and Community Rehabilitation services, including Occupational Therapy, Physiotherapy, Speech and Language Therapy, and Dietetics: Are any of these services currently delivered by external providers through: Insourcing Outsourcing Subcontracting For each external provider currently engaged, please provide: Name of the provider Type of engagement (insourced, outsourced, subcontracted) Service(s) provided Contract start date Contract end date or review date Annual contract value or total spend to date Volume of activity delivered (e.g. number of patients seen, sessions delivered, or hours worked) Performance metrics or KPIs, if available Was the contract awarded via a framework or open tender? If so, please specify which framework (e.g. NHS SBS, HealthTrust Europe, etc.). Who is the internal lead responsible for managing these contracts? Please provide their job title and department. Who do the external providers report into operationally within your organisation? (e.g. Clinical Lead, Service Manager) Are there any current or upcoming plans to procure additional external support for these services in the next 12 months? Have you experienced any challenges in meeting waiting time targets or service demand in these areas over the past 12 months?
Date of Response: 13/08/2025
View Response: 10371.pdf
Freedom of Information Request Reference: 10370
Date Received: 17/07/2025
Summary:
I am writing to request the following information under the Freedom of Information Act 2000: 1. Types of Spinal Surgeries o What types of spinal procedures are currently being performed at your hospital/trust? o Specifically, please indicate whether the following categories are included:  Deformity correction  Decompression procedures  Minimally Invasive Spine (MIS) surgery  Spinal fusion  Disc-related procedures (e.g. discectomy, disc replacement) 2. Volume of Procedures o How many spinal surgeries (broken down by type as per above) were performed in the past 12 months (or latest available full year)? o Please provide a monthly or quarterly breakdown if possible. 3. Key Spinal Surgeons o Please provide the names and positions of the consultant spinal surgeons currently performing spinal surgeries at your hospital/trust. o If possible, include any subspecialties (e.g., deformity, MIS, oncology, trauma). 4. Use of Bone Scalpel Technology o Is the BoneScalpel system (either Legacy or Nexus) used in any spinal procedures? o If not, please clarify:  Has the system been trialled previously?  Are clinicians or procurement staff aware of this technology? 5. Current Surgical Tools in Use o What instruments or technologies are currently being used for bone cutting during spinal surgery? o How old are the capital Devices o Are surgeons using traditional tools such as Kerrisons and osteotomes, or are ultrasonic devices such as Sonopet in use?
Date of Response: 28/08/2025
View Response: 10370.pdf
Freedom of Information Request Reference: 10369
Date Received: 17/07/2025
Summary:
Can you please provide an update on your Trust’s Infrastructure, including aspects of SaaS, Messaging, and eProcurement?
Date of Response: 14/08/2025
View Response: 10369.pdf
Freedom of Information Request Reference: 10368
Date Received: 17/07/2025
Summary:
Can I request, broken down by the calendar years 2021, 2022, 2023, 2024 and 2025 (most recent data): 1. How many nursing and midwifery shifts have gone unfilled after being put out for agency or bank cover, broken down by speciality and position.
Date of Response: 18/08/2025
View Response: 10368.pdf
Freedom of Information Request Reference: 10367
Date Received: 17/07/2025
Summary:
I am looking for information regarding the number of patients who have died whilst classified as a delayed discharge (a patient, clinically ready for discharge, cannot leave hospital because the other necessary care, support or accommodation for them is not readily accessible and/or funding is not available). As such, can I request the following: 1. A breakdown of the number for the financial years 2022/23 and 2023/24 (most recent); 2. How long each patient had been classified as a delayed discharge; 3) The hospital in which the patient was delayed and the cause of death; 4) Reason for delayed discharge.
Date of Response: 14/08/2025
View Response: 10367.pdf
Freedom of Information Request Reference: 10366
Date Received: 17/07/2025
Summary:
For the years 2019, 2020, 2021, 2022, 2023, 2024 and 2025 (most recent) The number of patients being removed from an NHS waiting list due to attending or being admitted at the private sector. [Please note: I am referring to patients who have chosen to pay for private treatment; NOT patients that are being treated as NHS patients at a private healthcare clinic].
Date of Response: 15/08/2025
View Response: 10366.pdf
Freedom of Information Request Reference: 10365
Date Received: 17/07/2025
Summary:
I would like to request information regarding your organisation's access to diagnostic scanning equipment and use of external CT, MRI and PET-CT scanning equipment, staff and services. Please see the below questions: How many PET-CT, CT and MRI scanners does the Trust have? (Not including any rented equipment). If the Trust uses external scanning support for PET-CT, CT or MRI, please provide details below for any contracts in place between 01/04/2024 and 31/03/2025. Provider Name Modality Number of scanners Staffed or Unstaffed Services Contract Start Date Contract End Date Number of scanning days in period or Service regularity (e.g., number of scanning days per week AND number of scanning weeks per month) Scanner Location(s) Reason being used (interim CDC, permanent CDC using mobiles, permanent CDC brick/mortar, waiting list management, scanner replacement project, Lung Health Check, other etc.) Extension options in contract
Date of Response: 19/08/2025
View Response: 10365.pdf
Freedom of Information Request Reference: 10364
Date Received: 17/07/2025
Summary:
Q1. How many early-stage (non-metastatic or Stages 1-3) non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab (Tecentriq) • Durvalumab (Imfinzi) • Nivolumab (Opdivo) • Pembrolizumab (Keytruda) • Chemotherapy • Radiotherapy • Chemotherapy AND Radiotherapy • Osimertinib Q2. How many patients has your trust treated in the last 3 months with Pembrolizumab for stage II Melanoma? Q3. How many patients has your Trust treated in total in the past 3 months for • Stage 2 Non-Small Cell Lung Cancer • Stage 3 Non-Small Cell Lung Cancer Q4. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Atezolizumab • Pembrolizumab monotherapy • Pembrolizumab with chemotherapy • Nivolumab • Osimertinib • Durvalumab • Chemotherapy • Radiotherapy • Chemotherapy and Radiotherapy Q5. How many Stage 2-3 non-small cell lung cancer (NSCLC) patients were treated in the past 3 months following surgery with: • Chemotherapy • Radiotherapy • Chemotherapy + Radiotherapy Q6. How many Stage 2-3 resectable non-small cell lung cancer (NSCLC) patients were treated in the past 3 months with: • Durvalumab
Date of Response: 14/08/2025
View Response: 10364.pdf
Freedom of Information Request Reference: 10363
Date Received: 17/07/2025
Summary:
Please provide me with a copy of your policy that covers supporting trans staff and gender inclusivity in the workplace, or equivalent. Please also confirm if your board still supports the contents of these policy documents in light of the For Women Scotland v Scottish Ministers case.
Date of Response: 14/08/2025
View Response: 10363.pdf
Freedom of Information Request Reference: 10362
Date Received: 17/07/2025
Summary:
I would like to request the following information regarding your hospital's use of disposable ports and disposable laparoscopic instruments over the last three financial years (2022/23, 2023/24, and 2024/25 ytd): 1. Disposable Surgical Laparoscopic Ports: o Total quantity purchased per year. o Total expenditure per year. o Top 5 suppliers used (by volume or value). o Whether your trust uses any reusable ports (yes/no). o If reusable ports are used: estimated percentage of surgeries where reusable ports are used versus disposable. 2. Disposable Laparoscopic Instruments: o Total quantity of disposable laparoscopic instruments purchased per year (e.g., graspers, scissors, dissectors). o Total expenditure on disposable laparoscopic instruments per year. o Top 5 suppliers used (by volume or value). o Does the trust use any reusable laparoscopic instruments? If yes, what is the estimated breakdown of disposable vs reusable instrument use (in percentage)? 3. Procurement and Sustainability o Is your trust currently reviewing the environmental impact or cost-effectiveness of disposable vs reusable laparoscopic instruments? o Are there any procurement policies or strategies in place to reduce reliance on single-use surgical instruments? 4. Contracts and Renewals a. Please provide the following information for any current contracts covering disposable ports or disposable laparoscopic instruments: o Name(s) of supplier(s) under contract. o Contract start and end dates. o Any planned renewal or re-tendering dates. o Estimated timeline for upcoming procurement decisions related to these items (if available). o Whether contracts are part of a national framework (e.g., NHS Supply Chain) or directly awarded.
Date of Response: 14/08/2025
View Response: 10362.pdf
Freedom of Information Request Reference: 10361
Date Received: 17/07/2025
Summary:
1. Please provide me with the number of discharged psychiatric patients (i.e General Psychiatry; Child and Adolescent Psychiatry; Forensic Psychiatry; Psychiatry of Old Age; Learning Disability; and Psychotherapy) in a)2022/23, b) 2023/24 and c) 2024/25 who received a follow-up appointment with community mental health services i) longer than 7 days, ii) longer than 10 days, and iii) longer 14 days
Date of Response: 12/08/2025
View Response: 10361.pdf
Freedom of Information Request Reference: 10360
Date Received: 16/07/2025
Summary:
1.1 Does your Trust / Health Board have an orthotics service and/or a prosthetics service? (Please tick yes even if the service is contracted to a private provider) ☐ Yes, we have both a prosthetics and orthotics service ☐ Yes, we have an orthotics service ☐ Yes, we have a prosthetics service ☐ No, we have neither an orthotics or prosthetics service either in-house or contracted to a private provider If the answer is “Yes” to having one or both services please answer section 2, and if the answer is “No” no further information is required. Section 2. 2.1 Is your orthotic and/or prosthetic service contracted to a private provider or ‘in-house’? (Please note, in-house means the prosthetic/orthotic clinicians are employed directly by the NHS). ☐ Our orthotics service is contracted to a private provider ☐ Our prosthetics service is contracted to a private provider ☐ Our orthotics service is in-house ☐ Our prosthetics service is in-house 2.2 How much funding did your Trust / Health Board receive from any and all government related bodies* for the prosthetic and/or orthotic service over the financial years 2020 – 2025 inclusive, and how much of that funding was given to the orthotics and/or prosthetics service budget (for in-house services) or the orthotics and/or prosthetics service contractor (for contracted services)? Please include the entire funding, including all pay and non-pay funding.
Date of Response: 28/08/2025
View Response: 10360.pdf
Freedom of Information Request Reference: 10357
Date Received: 16/07/2025
Summary:
The total number of patients who have been removed from cancer treatment waiting lists by your health board in the 2024 calendar year and the first 6 months of 2025 (January to present date of 16 July 2025).
Date of Response: 14/08/2025
View Response: 10357.pdf
Freedom of Information Request Reference: 10356
Date Received: 08/07/2025
Summary:
To inquire whether your organisation intends to come to market for bank or agency management services in the next 12 months. Specifically, I would appreciate information on: 1. Whether the trust plans to tender for these services in the near future. 2. The scope of services expected to be included in the upcoming tender. 3. The key point of contact within the trust responsible for this area.
Date of Response: 31/07/2025
View Response: 10356.pdf
Freedom of Information Request Reference: 10355
Date Received: 16/07/2025
Summary:
1. Commissioning of Complex Community Care: o Does your Health Board commission complex care and support in the community for individuals with significant clinical needs, such as those requiring a tracheostomy? o If so, please provide details of the types of services commissioned, including whether these are delivered directly by the NHS, through Health and Social Care Partnerships (HSCPs), local authorities, or via third-party providers. 2. Responsible Teams and Contacts: o Please provide the name(s), role(s), and contact details (email and/or phone number) of the team(s) or individual(s) responsible for arranging and overseeing complex care packages in the community. o If this responsibility lies with a specific HSCP or Integrated Joint Board (IJB), please indicate which one and provide relevant contact information.
Date of Response: 08/08/2025
View Response: 10355.pdf
Freedom of Information Request Reference: 10353
Date Received: 16/07/2025
Summary:
1. For the year 2024/2025 how much did your NHS Board spend on sugar-sweetened beverages and confectionery (eg chocolate, biscuits, cakes, sweets etc) for resale to patients, staff and the public? 2. For the year 2024/2025 how much did your NHS Board spend on diabetes-related medication, and could you specify, please, the proportion of this expenditure that was related to patients with type 2 diabetes?
Date of Response: 14/08/2025
View Response: 10353.pdf
Freedom of Information Request Reference: 10352
Date Received: 16/07/2025
Summary:
Question One How many patients were treated for Urothelial cancer (any stage) in the past 3 months with the following treatments: Atezolizumab (Tecentriq) Avelumab (Bavencio) Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Nivolumab (Opdivo) Cisplatin with Gemcitabine + Avelumab (Bavencio) Enfortumab Vedotin + Pembrolizumab (Padcev + Keytruda) Nivolumab (Opdivo) Pembrolizumab (Keytruda) Other active systemic anti-cancer therapy Palliative care only Erdafitinib Question Two How many patients have been treated for metastatic Urothelial cancer in the past 3 months with the following systemic anti-cancer therapies: Carboplatin single agent or in any other combination Carboplatin with Gemcitabine Carboplatin with Gemcitabine + Avelumab (Bavencio) Carboplatin with Paclitaxel Cisplatin single agent or in any other combination Cisplatin with Gemcitabine Cisplatin with Gemcitabine + Avelumab (Bavencio) Question Three Does your trust participate in any ongoing clinical trials for the treatment of urothelial cancer? If so, can you please provide the name of each trial along with the number of patients taking part?
Date of Response: 14/08/2025
View Response: 10352.pdf
Freedom of Information Request Reference: 10351
Date Received: 15/07/2025
Summary:
Can you tell me the total cost of medication dispensed to overseas visitors by NHS Lothian on GP10 in financial year April 24-25. By overseas visitors i refer to short stay visitors seen as temporary resident or int.
Date of Response: 13/08/2025
View Response: 10351.pdf
Freedom of Information Request Reference: 10350
Date Received: 15/07/2025
Summary:
I wish to make a Freedom of Information Request for the amount the organisation spent on locum Consultant Physicians in 2018, 2019, 2020, 2021,2022, 2023, 2024 & 2025 to the present date. Which a breakdown of each year.
Date of Response: 08/08/2025
View Response: 10350.pdf
Freedom of Information Request Reference: 10348
Date Received: 15/07/2025
Summary:
1. Has your health board moved to using recycled paper for patient letters, information and leaflets? 2. Please provide the number and nature of complaints, feedback or issues raised about the move to darker, recycled paper since recycled paper was introduced. 3. Please list any datixes or InPhase issues raised by staff as a result of the move to recycled paper. 4. Was any risk assessment completed in terms of accessibility for those who are visually impaired, before moving to recycled paper (eg the issues with visual contrast)? Please provide the risk assessment if completed.
Date of Response: 14/08/2025
View Response: 10348.pdf
Freedom of Information Request Reference: 10347
Date Received: 15/07/2025
Summary:
Please provide the number of orthopaedic crutches issued by your Trust between 2020 & 2025, and the associated annual cost. Please also provide the number of crutches returned (% return rate) and any internal policies regarding reuse or recycling.
Date of Response: 13/08/2025
View Response: 10347.pdf
Freedom of Information Request Reference: 10344
Date Received: 15/07/2025
Summary:
I want to know the following about the Orthognathic waiting list in Lothian: 1. How many patients were on the list when it was closed? 2. How many patients are on the waiting list now? 3. How many patients were on the waiting list a year ago? 4. How many patients are now in treatment? 5. How many patients were in treatment a year ago?
Date of Response: 14/08/2025
View Response: 10344.pdf
Freedom of Information Request Reference: 10343
Date Received: 14/07/2025
Summary:
Please could you provide the following data for the past two calendar years (or most recent available), broken down by year: 1. Cancer Staging at Diagnosis o The number and percentage of patients diagnosed with cancer at each stage (Stage 1, Stage 2, Stage 3, Stage 4), by cancer type if possible. 2. Time from Referral to Diagnosis o The average and median number of days between urgent GP referral (2-week wait or equivalent) and confirmed cancer diagnosis. 3. Time from Diagnosis to First Treatment o The average and median number of days between confirmed diagnosis and start of first treatment (e.g. surgery, chemotherapy, radiotherapy), by cancer type if possible. 4. Delays or Breaches of Waiting Time Targets o The number of patients whose treatment did not begin within the nationally recommended waiting time targets (e.g. 62 days from urgent referral), broken down by year and cancer type.
Date of Response: 11/08/2025
View Response: 10343.pdf
Freedom of Information Request Reference: 10342
Date Received: 14/07/2025
Summary:
This is a FOI request on procedures and policies of the adult psychiatry units of NHS Scotland - Lothians. I request all information on the pathways through which guanfacine can be prescribed to adult psychiatry patients for relevant symptoms and conditions (e.g. Including but not limited to ADHD, borderline personality disorder, etc).
Date of Response: 14/08/2025
View Response: 10342.pdf
Freedom of Information Request Reference: 10341
Date Received: 14/07/2025
Summary:
When you receive a subject access request for medical records electronically, do you provide them electronically or in hard copy format?
Date of Response: 18/07/2025
View Response: 10341.pdf
Freedom of Information Request Reference: 10340
Date Received: 14/07/2025
Summary:
1) The number of employees who have failed drugs or alcohol tests for each month since March 1, 2022 to date 1a) Please break this down by staff seniority level, location of failed drugs or alcohol test and type of drug found if applicable. 1b) For the avoidance of doubt, please provide the number of non-negative test results, and for each of these, the number which were confirmed positive after being sent for 'back-to-lab' testing. 2) A list of the randomised drug and alcohol tests undertaken over the same time period. This should include the location (i.e. hospital or office), date, and number of employees tested at that test, including the number of failures.
Date of Response: 08/08/2025
View Response: 10340.pdf
Freedom of Information Request Reference: 10339
Date Received: 16/07/2025
Summary:
Questions in relation to ADHD assessments.
Date of Response: 21/08/2025
View Response: 10339.pdf
Freedom of Information Request Reference: 10338
Date Received: 14/07/2025
Summary:
Can you advise the number of adults who died while on the waiting list for an assessment for autism and/or ADHD? If you have that information can you confirm cause of death?
Date of Response: 12/08/2025
View Response: 10338.pdf
Freedom of Information Request Reference: 10337
Date Received: 11/07/2025
Summary:
I am keen to understand the reasons for A&E attendances. As such, can you provide the following for the financial years 2014/15 to 2024/25 (11 financial years) The total number of A&E attendances; The total number of mental-health related A&E attendances; The top five reasons/categories for A&E attendance.
Date of Response: 22/08/2025
View Response: 10337.pdf
Freedom of Information Request Reference: 10336
Date Received: 11/07/2025
Summary:
How many ovarian cancer patients (any stage) have been treated in the last 3 months with: Paclitaxel in combination with a platinum-based compound Platinum-based therapy alone (cisplatin or carboplatin) Bevacizumab in combination with paclitaxel and carboplatin Olaparib Olaparib + Bevacizumab Niraparib Rucaparib Does your trust participate in any clinical trials for the treatment of ovarian cancer? If so, please provide the name of each trial along with the number of patients taking part
Date of Response: 11/08/2025
View Response: 10336.pdf
Freedom of Information Request Reference: 10335
Date Received: 11/07/2025
Summary:
Please provide details on the following Multiple sclerosis (MS) staff within your Health Board area: -The number of Rehabilition Consultants -The number of Consultant Neurologists
Date of Response: 28/08/2025
View Response: 10335.pdf
Freedom of Information Request Reference: 10334
Date Received: 11/07/2025
Summary:
From 1st April 2025 to 30th June please provide a breakdown of: Total trust spend with framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: Spend per band Spend per specialty Spend per agency name In the period 1st April 2025 to 30th June please provide a breakdown of: Total trust spend with off-framework agencies for locum AHP/HSS staffing. Please provide a further breakdown for locum AHP/HSS staffing by: Spend per band Spend per specialty Spend per agency name In the period 1st April 2025 to 30th June please provide a breakdown of: Total trust spend with the internal trust bank or associated external provider for locum AHP/HSS staffing Please provide a further breakdown for locum AHP/HSS staffing by: Spend per grade Spend per specialty Spend per internal or associated external provider Please confirm your allocated budget for agency locum AHP/HSS staffing for the period 1st April 2025 to 30th June
Date of Response: 11/08/2025
View Response: 10334.pdf
Freedom of Information Request Reference: 10333
Date Received: 11/07/2025
Summary:
Please provide the total amount spent on locum Doctors across all departments. for 2025 YTD and 2024 Can you break down the percentage spent on bank/locum Doctor spend on the last year (2024) to the most recent records you have, compared to the year before (2023)? How many Doctor vacancies do you currently have within the Trust that have been vacant for over 6 months? Do you have any cost-saving measures in place? Locum-to-permanent ratio: How many locum doctors are currently employed versus permanent doctor staff, and what is the rationale for using locums instead of permanent? Please share which departments have the highest locum doctor spend due to them not being able to fill hard-to-fill roles?
Date of Response: 11/08/2025
View Response: 10333.pdf
Freedom of Information Request Reference: 10332
Date Received: 11/07/2025
Summary:
- Number of mental health patients experiencing delayed discharge: Please provide the total number of mental health inpatients who experienced delayed discharge in your health board area for each of the last two calendar years (or financial years), broken down by year. - Length of delayed discharge: Please provide the average and longest number of days patients remained in hospital in your health board area after being medically fit for discharge, for each year. - Main reasons for delayed discharge: Please provide a breakdown of the primary reasons for delayed discharges among mental health patients (housing issues, lack of social care support, etc.) for each year. - Age and diagnosis categories: If available, please provide data broken down by age groups (under 18, 18–65, over 65) and primary mental health diagnosis category. - Costs associated with delayed discharges: If possible, please provide estimates of the financial cost of delayed discharges for mental health patients for each of the last two years.
Date of Response: 18/08/2025
View Response: 10332.pdf
Freedom of Information Request Reference: 10331
Date Received: 11/07/2025
Summary:
Policy of NHS Lothian and the services available for visitors (who are registered with another Health Board in Scotland) but who are visiting the Lothian area to received GP provided services such as blood tests for diabetes or coagulant testing. If this is not able to be provided by GPs, what services are provided at A&E for these tests.
Date of Response: 14/08/2025
View Response: 10331.pdf
Freedom of Information Request Reference: 10330
Date Received: 11/07/2025
Summary:
Can you provide the following for the financial years 2014/15 to 2024/25 (11 financial years) the total a) available outpatient appointments; b) used outpatient appointments; and c) unused outpatient appointments (unused appointments counts appointments that were unfilled or cancelled). the total a) cancelled outpatient appointments; b) cancelled outpatient appointments for non-clinical/capacity reasons.
Date of Response: 19/08/2025
View Response: 10330.pdf
Freedom of Information Request Reference: 10329
Date Received: 10/07/2025
Summary:
Broken down for the financial years 2014/15 to 2024/25 (11 financial years), The total number of whistleblowing concerns that were reported. Before the National Whistleblowing Standards were introduced on 1 April 2021, the number of concerns that were a) upheld; b) not upheld. Since the National Whistleblowing Standards were introduced on 1 April 2021: The number of whistleblowing concerns that were reported to the board at stage 1. How many of those concerns were resolved at stage 1 or were referred on to be looked at in more detail stage 2 or beyond. 2. Since the National Whistleblowing Standards were introduced on 1 April 2021: The number of whistleblowing concerns that were reported to the board at stage 2. How many of those concerns were resolved at stage 2 or were referred to the Independent National Whistleblowing Officer. Since the National Whistleblowing Standards were introduced on 1 April 2021: The number of whistleblowing concerns that were referred to the Independent National Whistleblowing Officer. The outcome of the referral and investigation.
Date of Response: 11/08/2025
View Response: 10329.pdf
Freedom of Information Request Reference: 10327
Date Received: 10/07/2025
Summary:
Can you provide the total number of direct GP appointments delivered in each of the financial years 2014/15 to 2024/25 (11 financial years).
Date of Response: 17/07/2025
View Response: 10327.pdf
Freedom of Information Request Reference: 10326
Date Received: 10/07/2025
Summary:
Freedom of Information questions: 1. Organisation’s name 2. Under the Freedom of Information Act, will you be reporting the use, research, purchase, development, or otherwise of an XR technology within your organisation? · Yes · No, there are no XR products to report in my organisation 3. Does your organisation have an established XR Technology Lab or Centre of Excellence for XR Technology? · Yes · No · Other 4. Please select the type of organisation that you represent: · Academic Institution/ University · NHS Acute Trust (Hospital Trust) · NHS Mental Health Trust · NHS Ambulance Services Trust · NHS Community Health Trust · NHS Foundation Trust · NHS Specialist/Integrated Trust · Health Board (Scotland/Wales) · Health and Social Care Trust (NI) · Other 5. Please select the nature of your organisation's involvement with XR health products (please select all that are applicable) · We are using free XR products · We are using XR products that we have purchased · We are researching XR products · We are developing XR products · Other 6. Please state the name of the product(s) 7. Please provide a brief description of the product(s) 8. Please highlight any unique features of the product(s) 9. Please provide a link to the product website(s) if available 10. Please select the most relevant categories for the product(s) being developed or deployed: · Mental Wellbeing and Therapy · Physiotherapy and Rehabilitation · Pain Management · Clinical & Surgical · Patient Education and Training · Workforce Education and Training · Healthy Lifestyle and Fitness · Other 11. Please select how these product(s) are being or will be adopted: · Free to patients/staff · Paid for by patients/staff · Free to NHS · Paid for by NHS · Unknown · Other 12. Please select the level of maturity of the product(s) · Proof of concept · Minimum Viable Product · Early Adoption · Growing Integration · Established Practice · Unknown · Other 13. Approximately what date/year was the XR product(s) first deployed within your organisation? 14. Where and/or in how many locations is the product(s) currently offered? 15. How is the product(s) currently distributed? · Home use by patients · Home use by staff · NHS site by patients · NHS site by staff · Unknown · Other 16. Please select the hardware that is used in your organisation (select all that apply): · Meta Quest 2 · Meta Quest 3 · Meta Quest Pro · Pico 4 · Pico Neo 3 Pro / Eye · HTC Vive XR Elite · Lenovo ThinkReality XVR · Valve Index · Apple Vision Pro · HTC VivePro 2 · Pimax Crystal · Sony Playstation VR2 · Vive Focus 3 · Unknown · Other 17. If your organisation is involved in the development of XR products, please select the development software that is used (please select all that apply): · Unity · Unreal Engine · Godot · Open XR · XR Interaction Toolkit · SteamVR Plugin · Meta XR SDK · Vive Wave SDK · Varjo SDK · WebXR · Mixed Reality Toolkit · Ultraleap Hand Tracking · Unknown · Other 18. Please provide details of external organisations such as development partners that are involved 19. Please provide any further details
Date of Response: 01/08/2025
View Response: 10326.pdf
Freedom of Information Request Reference: 10325
Date Received: 10/07/2025
Summary:
I am keen to understand theatre capacity in your Health Board's hospitals. As such, can you provide the following for the financial years 2014/15 to 2024/25 (11 financial years) On theatre hours: the total a) available theatre hours; b) used theatre hours; and c) unused theatre hours (unused hours counts gaps between patients, late starts, early finishes & unused sessions). On theatre sessions: the total a) available theatre sessions; b) used theatre sessions; and c) unused theatre sessions.
Date of Response: 22/08/2025
View Response: 10325.pdf
Freedom of Information Request Reference: 10241
Date Received: 17/06/2025
Summary:
Please provide the following information: • A copy of the Health Board’s current policy or policies governing the provision of accommodation for children to reside in an in-patient setting due to their mental health (including the placement of children at a place alongside or separately from adults). Please provide confirmation of when these were last reviewed. • The number of beds available within the geographical area of the Health Board, for children to reside on an in-patient basis due to their mental health, at a place separately from adults. Please provide the number (out of the maximum available) which were in use, year by year, for the past five calendar years (with an update for 2025 year to date). • The number of children within the geographical area of the Health Board, residing on an inpatient basis due to their mental health, at a place separately adults. Please provide the number (out of the maximum available) which were in use, year by year, for the past five calendar years (with an update for 2025 year to date). • The number of children within the geographical area of the Health Board, residing on an inpatient basis due to their mental health, at a place alongside adults. Please provide the number (out of the maximum available) which were in use, year by year, for the past five calendar years (with an update for 2025 year to date). • Details of any plans to increase the number of beds available within the geographical area of the Health Board for children to reside at mental health in patient units at a place separately from adults. The number of beds this will provide and when these will become available.
Date of Response: 29/08/2025
View Response: 10241.pdf
Freedom of Information Request Reference: 10279
Date Received: 30/06/2025
Summary:
I wish to request guidelines, policies, proforma documents and any other document available, as at June and July 2022, relating to the following: • Identification and management of reduced fetal movement; • Assessment and recording of symphysis fundal height; • Management of reduced symphysis fundal height; • Symphysis fundal height measurement and recording chart Please provide information from both the obstetric/medical and midwifery perspectives.
Date of Response: 25/08/2025
View Response: 10279.pdf
Freedom of Information Request Reference: 10242
Date Received: 17/06/2025
Summary:
Please provide the following information: • A copy of the Health Board’s current policy or policies governing the use of restrictive practices (such as restraint, seclusion and intramuscular injection) on children in mental health settings (including in relation to the recording and reporting of incidents). Please provide confirmation of when these were last reviewed. • The number of i) children and ii) incident of children being restrained in mental health in-patient settings operated by the Health Board in each of the last five calendar years (with an update for 2025 year to date). • The number of i) children and ii) incident of children being subject to seclusion in mental health in-patient settings operated by the Health Board in each of the last five calendar years (with an update for 2025 year to date). • The number of i) children and ii) incident of children being, subject to intermuscular injection of sedatives in mental health in-patient settings operated by the Health Board in each of the last five calendar years (with an update for 2025 year to date). • The number of i) children and ii) incident of children being injured as a result of restrictive practices in mental health in-patient settings operated by the Health Board in each of the last five calendar years (with an update for 2025 year to date). • The number of i) children and ii) incident of children being, taken to A&E as a result of restrictive practices in in-patient settings operated by the Health Board in each of the last five calendar years (with an update for 2025 year to date).
Date of Response: 05/08/2025
View Response: 10242-1.pdf
Freedom of Information Request Reference: 10175
Date Received: 02/06/2025
Summary:
I would like answers to the below questions around ASD & ADHD referral, assessment & strategy. Timescale: Last 12 months & current situation 1) ASD adults: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? 2) ASD children & adolescents: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? 3) ADHD adults: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? 4) ADHD children & adolescents: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? If the above specific data is unavailable, I would like to request the following: 5) Adults awaiting Neurodevelopmental Assessment: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? 6) Children & adolescents awaiting Neurodevelopmental Assessment: • As at today's date, how many people are on the NHS waiting list awaiting assessment in my NHS area? • How many total referrals has the NHS received in the last 12 months in my NHS area? • How many assessments has the NHS carried out in my NHS area? • What is the estimated waiting time for assessment as at today's date in my NHS area? • Who carries out assessments in my NHS area? • How many individuals are qualified to carry out assessments in my NHS area? • How much has been spent on assessment in the last 12 months in my NHS area? 7) And finally, What is the current NHS strategy for assessment, diagnosis & support of neurodevelopmental differences in adults, children & adolescents?
Date of Response: 27/08/2025
View Response: 10175.pdf
Freedom of Information Request Reference: 10015
Date Received: 23/04/2025
Summary:
1. Room Conversions: The total number of rooms at REH that were not originally constructed or designated as patient bedrooms (eg, staff offices or similar spaces), which have been converted or repurposed and used on an ad-hoc basis to accommodate patients at any point over the past twelve months. 2. Patient Use: The total number of individual patients who have been accommodated in such rooms at any time during their inpatient stay at REH within the past twelve months. 3. Patient-Days in Non-Clinical Rooms: The total number of patient-days associated with such accommodation at REH over the past twelve months. (That is, the cumulative total of days each patient spent in these repurposed rooms.) 4. Copies of any risk assessments undertaken prior to allowing patients to use such rooms, identifying for example any risks in terms of ligature points or otherwise.
Date of Response: 27/08/2025
View Response: 10015.pdf
Freedom of Information Request Reference: 10324
Date Received: 10/07/2025
Summary:
What was the average waiting time for urology patients between 2020 and 2025? Please break down by year and by outpatients and inpatients. How many patients are on the urology waiting list between 2020 and 2025? Please break down by year. How many patients received a urology appointment between 2020 and 2025? Please break down by year. How many urology appointments were missed between 2020 and 2025? Please break it down per year. How many urology appointments were cancelled, or cancelled and rescheduled, between 2020 and 2025? Please break it down per year. How many frontline urology staff does the health board have? Please break it down per year from 2020 to 2025, and break down to doctors/consultants, nurses and physiotherapists, etc. How many referrals for a hospital urology appointment were made between 2020 and 2025? Please break it down per year and indicate where these referrals came from, e.g. GP, specialist clinic, etc. Please list the five most common urology conditions patients are seeking treatment for in your health board area.
Date of Response: 08/08/2025
View Response: 10324.pdf
Freedom of Information Request Reference: 10323
Date Received: 10/07/2025
Summary:
In the last 3 months (April, May, June 2025), how many haemophilia A and B and von Willebrand patients were treated with the following coagulation factors in your trust and how much volume (IUs or mg) was used? Number of treated patients Volume used (IUs, mg) Hemlibra (non-inhibitor patients) Hemgenix Altuvoct Advate Adynovi Elocta Esperoct NovoEight ReFacto AF Nuwiq Hympavzi Idelvion Refixia Alprolix BeneFIX Replenine Rixubis Veyvondi Voncento Wilate Willfact
Date of Response: 07/08/2025
View Response: 10323.pdf
Freedom of Information Request Reference: 10320
Date Received: 09/07/2025
Summary:
I am writing to request an internal review of NHS Lothian’s response to my Freedom of Information requests, 10217/18/19/20 My original request sought: clarification on staff parking, CCTV footage and body camera footage, departmental complaints. The reference for these requests are 10217/18/19/20, where all of the minute information can be found. Please understand that the footage and complaints I am requesting are largely of myself so I do not see why confidentiality would apply here at all The response I received on 04/07 refused the request on grounds I believe to be unjustified. I believe the use of section 38(1) (b) is overly broad I requested procedural information with redacted content, neither of which necessarily identifies individuals. Under the Freedom of Information (Scotland) Act 2002, I am entitled to a review of this decision. I would appreciate a reassessment of the decision and a clearer justification if the refusal is upheld.
Date of Response: 30/07/2025
View Response: 10320.pdf
Freedom of Information Request Reference: 10319
Date Received: 09/07/2025
Summary:
Does your organisation currently have an established osteoporosis clinical pathway, care pathway or equivalent in place (either independently or in collaboration with providers such as hospitals, community services, or primary care)? If yes: Please provide a copy of the osteoporosis pathway document (or the most recent version available). Please confirm the date the pathway was last reviewed or updated. If no pathway currently exists: Please confirm whether your organisation has any plans to develop or adopt an osteoporosis pathway within the next 12 months. If available, please provide details of any related initiatives, working groups, or regional coordination efforts in place for managing osteoporosis care.
Date of Response: 31/07/2025
View Response: 10319.pdf
Freedom of Information Request Reference: 10318
Date Received: 09/07/2025
Summary:
I am writing to request information under the FOI Act about your CAMHS services/neurodevelopmental assessment services for Children and Young People. If you cannot provide this information, please tell me where I can find it. Please tell me: 1:The number of young people on your waiting list for a first appointment (assessment) as of the date of this email or nearest available. 2: The average length of time young people are currently waiting between referral and first appointment (assessment) 4: The average length of time young people are currently waiting between initial referral and first therapeutic intervention. 5: How many young people assessed were not offered follow up treatment at Camhs in the year 2024-25, as a number and a proportion of the total of young people assessed? 6: The longest time any young person has been on your current waiting list (as of the date of the receipt of this email or nearest) 7: The average wait between referral and assessment for neurodevelopmental/neurodiverse conditions on the date of this request or nearest available data. 8: The number of young people on the waiting list for neurodevelopmental/neurodiverse assessments on the date of this request or nearest available data.
Date of Response: 07/08/2025
View Response: 10318.pdf
Freedom of Information Request Reference: 10317
Date Received: 10/07/2025
Summary:
I wish to make a Freedom of Information Request review on the grounds that multiple other health boards have so far been able to provide me with their figures & not a link NHS Lothian have done.
Date of Response: 08/08/2025
View Response: 10317.pdf
Freedom of Information Request Reference: 10316
Date Received: 08/07/2025
Summary:
I am writing to make an open government request for all the information to which I am entitled under the FOI Act 2000. 1. What is your whole Trust’s IT spend for the following financial year?: FY 2023/2024 (£): FY 2024/2025 (£): DEFINITION: Please include in your IT spend calculation the capital and revenue cost of your IT staff, Software, Services, Hardware, Communication equipment and Other IT spend for the requested financial year. 2. Based on your most recent Digital Maturity Assessment (DMA) submission to NHS England in 2024 (and 2025, if completed), please provide the following: a) Your overall DMA score (on a scale of 1.0 to 5.0). b) If readily available, the individual scores for each of the seven DMA pillars: • Empower Citizens • Ensure Smart Foundations • Healthy Populations • Improve Care • Safe Practice • Support People • Well Led DEFINITION: The Digital Maturity Assessment (DMA) is a self-assessment tool used by NHS organisations to evaluate their readiness for digital transformation. The overall score is usually the average of seven pillars, each scored from 1.0 (least mature) to 5.0 (most mature). The pillars are: Empower Citizens, Ensure Smart Foundations, Healthy Populations, Improve Care, Safe Practice, Support People, and Well Led. 3. Based on your most recent HIMSS EMRAM and HIMMS INFRAM assessment/ self-assessment, please provide the following: Which HIMSS EMRAM score have your Trust currently achieved (0-7): Which HIMSS INFRAM score have your Trust currently achieved (0-7): Do you have plans to reassess, if your Trust is working towards achieving a new HIMSS EMRAM or INFRAM level, what level is this, and when will it be achieved: Definitions: Electronic Medical Record Adoption Model (EMRAM) – is an eight-stage model, scored from stages zero (least mature) to seven (most mature). At each stage, organisations need to demonstrate a progressive and eventual removal of paper, higher pervasiveness of use and compliance statistics, and an increasing reliance on automation and clinical decision support. Infrastructure Adoption Model (INFRAM) – The eight-stage INFRAM measures the maturity of a healthcare facility's IT infrastructure across five areas: mobility, security, collaboration, transport and data centre.
Date of Response: 31/07/2025
View Response: 10316.pdf
Freedom of Information Request Reference: 10315
Date Received: 08/07/2025
Summary:
Please can I request the below information on the utilisation of Insourcing for the following period 01/04/2025-30/06/2025 Total spend during the period for Insourcing for the below specialties: • Neurology • Neurophysiology • Dermatology • Gastroenterology • Endoscopy • Cardiology • Respiratory • Orthodontics / Dental • OMFS • ENT • Rheumatology • Gynaecology • Ophthalmology • Surgery- including all subspecialties Please break the spend down by insourcing company. Please confirm if there was a budget for insourcing for the specialties outlined during the same period. What was the service type relating to the specialties outlined, for example, outpatient, diagnostic or theatres. Was it a fully managed service or Team provision. Please can you confirm the Frameworks utilised for each specialty. Please confirm any direct awards or mini competitions which are being utilised for each specialty. Total procedures completed by insourcing companies for the specialties outlined during the same period.
Date of Response: 31/07/2025
View Response: 10315.pdf
Freedom of Information Request Reference: 10314
Date Received: 07/07/2025
Summary:
Between 1st January 2025 and 31st May 2025: 1. In monetary terms, how much did your Trust spend by individual hospital, on either repairing flexible endoscopes and/or spend on service contracts? 2. How many loan endoscopes were used? 3. What was the total number of endoscopes that were sent to be repaired? 4. How many endoscopes were returned for repair due to damage? 5. How many procedures were cancelled due to insufficient endoscope availability? 6. What is the most frequent cause for endoscopes to be repaired? 7. Do you use an endoscope distal tip protector? a. If yes, which product are you using? 8. Is an endoscope distal tip protector used routinely in the drying cabinet? 9. Does the endoscopy unit use disposable or reusable valves? a. If using disposable valves, how much was spent on disposable valves between 1st January 2025 and 31st May 2025? 10. How is maximum traceability of reusable endoscope valves maintained during endoscope decontamination? 11. Does the Trust use a valve basket to keep the valves together? a. If yes, which one do you use? 12. Are the endoscope valves kept with the endoscope for the duration of the decontamination process? a. If yes, how is this maintained? 13. How often are endoscope reusable valve sets replaced?
Date of Response: 04/08/2025
View Response: 10314.pdf
Freedom of Information Request Reference: 10313
Date Received: 07/07/2025
Summary:
For each month of 2020/21, 2021/22, 2022/23, 2023/24, 2024/25 and 2025/26 (most recent): 1. The number of staff working hours. 2. The number of working hours lost to staff sickness absence. 3. The number of working hours lost to staff sickness absence due to stress. (For clarification, if ‘stress’ is not available as a separate category please provide the name of the category it falls under and the total number of absent hours registered under this category).
Date of Response: 06/08/2025
View Response: 10313.pdf
Freedom of Information Request Reference: 10312
Date Received: 07/07/2025
Summary:
Non Medical Non Clinical ( NMNC) temporary agency spend for Ancillary, admin and clerical and corporate functions staff in the last 12 months. Non Medical Non Clinical ( NMNC) permanent agency spend for Ancillary, admin and clerical and corporate functions staff in the last 12 months. A Breakdown by spend of suppliers used for NMNC agency staff in the last 12 months Confirmation of the Framework you use for NMNC agency staff ( eg Crown Commercial Services or Health Trust Europe. ) Name of Procurement manager and their email address
Date of Response: 07/08/2025
View Response: 10312.pdf
Freedom of Information Request Reference: 10311
Date Received: 07/07/2025
Summary:
Q1. Please provide the total number of patients treated in the last 6 months for: •Polycythaemia Vera (ICD10 code D45) •Myelofibrosis (ICD10 code D47.4) •Myelofibrosis (ICD10 code D47.4) patients aged 65 and older Q2. How many patients were treated in the past 6 months (for any disease) with: •Ruxolitinib •Fedratinib •Momelotinib Q3. How many patients were treated with Ruxolitinib in the past 6 months for the following diseases? •Myelofibrosis (ICD10 code D47.4) •Polycythaemia Vera (ICD10 code D45) •Other/Unknown Q4. How many myelofibrosis (ICD10 code D47.4) patients has your trust diagnosed in the past 3 years? •Of these patients, how many were treated in the past 6 months with Hydroxycarbamide? •Of these patients, how many were treated in the past 6 months with Interferon therapy? •Of these patients, how many have received no active treatment in the past 6 months? Q5. Does your trust participate in any clinical trials for the treatment of myelofibrosis? If so, can you please provide the name of each trial along with the number of patients taking part.
Date of Response: 06/08/2025
View Response: 10311.pdf
Freedom of Information Request Reference: 10310
Date Received: 07/07/2025
Summary:
I am currently reviewing information about PRS for Music and have accessed the available materials published to date. However, I would like to ensure I have the most recent and accurate understanding of membership criteria, licensing, and any recent developments or policy updates.
Date of Response: 08/08/2025
View Response: 10310.pdf
Freedom of Information Request Reference: 10309
Date Received: 07/07/2025
Summary:
1. The longest waiting time for initial contact for children and young people’s speech and language therapy in May 2025. 2. In May 2025, please tell us how many people were waiting for initial contact for children and young people’s speech and language therapy. Please break this down by numbers waiting Less than 12 weeks, 12 to 18 weeks, 19 weeks to 26 weeks, 27 weeks to 52 weeks, 1 year to 2 years and over two years. 3. The longest wait for individualised therapy in May 2025. 4. Please detail the health substantive core funding committed for children and young people’s speech and language therapy for the current business year – 2025/26. 5. Please detail the external funding committed for children and young people’s speech and language therapy for the current business year – 2025/26. List by type of funding, i.e. core service level agreement(s) with relevant local authorities, attainment challenge, early years, pupil equity fund, 3rd Sector etc. 6. Please confirm how many whole time equivalent (WTE) speech and language therapist assistants were employed in the children’s speech and language therapy service in May 2025. 7. In addition, please confirm the headcount of speech and language therapy assistants (i.e. individual staff members, regardless of WTE) working in the same service during that period.
Date of Response: 04/08/2025
View Response: 10309.pdf
Freedom of Information Request Reference: 10308
Date Received: 07/07/2025
Summary:
Please provide the number of FTE individuals employed by your organisation in a counselling role within adult services for each of the past five financial years (2019/20 to 2023/24 inclusive), broken down by year. If available, I would also appreciate a breakdown by: 1. Employment type (e.g. full-time, part-time, sessional) 2. Service area or team (e.g. adult mental health, primary care, addiction services, community wellbeing hubs, etc.) 3. Whether they were directly employed by your organisation or contracted via a third party
Date of Response: 08/08/2025
View Response: 10308.pdf
Freedom of Information Request Reference: 10307
Date Received: 07/07/2025
Summary:
In each of the past 10 financial years and the current financial year (2014/15 – 2025/26), broken down by both hospital and month. 1. How many patients waited over a) 15 minutes; b) 30 minutes; c) 45 minutes) d) one hour to be triaged? 2. What was the longest A&E triage time?
Date of Response: 01/08/2025
View Response: 10307.pdf
Freedom of Information Request Reference: 10305
Date Received: 07/07/2025
Summary:
For each of the past 10 financial years and the current financial year (2014/15 – 2025/26): 1. The total number of adverse incidents reported with a risk to patient safety. 2. The proportion of these patient safety related adverse incidents that caused a) no harm, b)low harm, c)moderate harm, d) severe harm, and e) death. 3. The number of these patient safety related adverse incidents due to an issue with estates or facility failures. 4. The adverse incidents reporting a) wrong site surgery, b) retained object post-procedure, and c) wrong implant/prosthesis
Date of Response: 01/08/2025
View Response: 10305.pdf
Freedom of Information Request Reference: 10304
Date Received: 07/07/2025
Summary:
• Please provide the number of patients diagnosed with a brain tumour in each of the last 5 years. • Please provide this information broken down by the number of (i) malignant and (ii) benign tumours. • Please outline the referral and diagnosis process for a patient presenting with brain tumour symptoms resident in your health board area.
Date of Response: 01/08/2025
View Response: 10304.pdf
Freedom of Information Request Reference: 10303
Date Received: 07/07/2025
Summary:
1. In your organisation, do you employ “job planning” for pharmacists (job planning in this instance is typically the division of a working week into half day "sessions" allocated to commitments such as clinical work, development, supporting professional activities time, teaching, research, etc)? 2. How many pharmacists do you employ? Please state headcount 3. Of the pharmacists that you employ, how many have job plans? 4a. For each pharmacist with a job plan, please provide the proportion of contracted hours allocated to protected* time for supporting professional activities (SPA), also known as protected learning time or professional development time 4b. For each pharmacist without a job plan, please provide the proportion of contracted hours allocated to protected time for supporting professional activities (SPA), also known as protected learning time or professional development time 5. If it is not possible to provide an answer to question 4a or 4b, please provide the recommended allocation to supporting professional activities (SPA), also known as protected learning time or professional development time, in hours per week for a full-time employed pharmacist.
Date of Response: 01/08/2025
View Response: 10303.pdf
Freedom of Information Request Reference: 10302
Date Received: 07/07/2025
Summary:
• The number of recorded Hospital Acquired Infections in the calendar years 2023, 2024 and 2025 to date. Please indicate what the infection was in each case, for example staphylococcus aureus bacteraemia, clostridioides difficile, etc. • The number of recorded deaths from Hospital Acquired Infections in the calendar years 2023, 2024 and 2025 to date. Please indicate what the infection was in each case, for example staphylococcus aureus bacteraemia, clostridioides difficile, etc. • The number of recorded Healthcare Associated Infections in the calendar years 2023, 2024 and 2025 to date. Please indicate what the infection was in each case, for example staphylococcus aureus bacteraemia, clostridioides difficile, etc. • The number of recorded deaths from Healthcare Associated Infections in the calendar years 2023, 2024 and 2025 to date. Please indicate what the infection was in each case, for example staphylococcus aureus bacteraemia, clostridioides difficile, etc.
Date of Response: 05/08/2025
View Response: 10302.pdf
Freedom of Information Request Reference: 10301
Date Received: 04/07/2025
Summary:
• For referrals that were accepted by CAMHS, the average number of appointments which were attended prior to being discharged. Please provide figures for each year from 2015 to 2025 inclusive. • The range of attended appointments (i.e. the lowest and highest number of attended appointments) for each year in this period. • Whether child patients referred for neurodevelopmental assessments are included in any of these years’ figures and if so which years.
Date of Response: 01/08/2025
View Response: 10301.pdf
Freedom of Information Request Reference: 10300
Date Received: 04/07/2025
Summary:
Questionnaire in relation to robotic device and software applications.
Date of Response: 01/08/2025
View Response: 10300.pdf
Freedom of Information Request Reference: 10299
Date Received: 04/07/2025
Summary:
Q1. Does your trust provide SACT (systemic anti-cancer therapy) treatments for endometrial cancer? If not, which other trust do you refer endometrial cancer patients to for SACT treatments? Q2. How many patients were treated for endometrial cancer (any stage) in the past three months with the following treatments: • Dostarlimab (Jemperli) • Dostarlimab (Jemperli) AND Chemotherapy • Hormone therapy (Progesterone or Letrozole) • Pembrolizumab (Keytruda) monotherapy • Lenvatinib + Pembrolizumab (Lenvima +Keytruda)  • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy Q3. In the past three months, how many patients were treated for recurrent endometrial cancer after having previously received platinum-based chemotherapy? Q4. In the past three months, how many patients were treated for endometrial cancer with the following as first line treatments: • Dostarlimab (Jemperli) AND Chemotherapy • Durvalumab with platinum-based chemotherapy • Pembrolizumab with platinum-based chemotherapy • Hormone therapy (Progesterone or Letrozole) • Platinum-based chemotherapy (monotherapy or combination with taxanes, anthracyclines, cyclophosphamide) • Any other SACT • Any other chemotherapy Q5. Does your trust participate in any clinical trials for the treatment of endometrial cancer? If so, can you please provide the name of each trial and the number of patients taking part?
Date of Response: 17/07/2025
View Response: 10299.pdf
Freedom of Information Request Reference: 10298
Date Received: 04/07/2025
Summary:
Over the past financial year 2024-2025: • Please provide a list of the currently vacant GP posts in your health board area which have been advertised on more than one occasion (i.e. been re-advertised). • How many times has each post been advertised? • Each time it was advertised, how many applications were received? • What is the longest that any currently vacant GP post has been unfilled? • Where is this vacancy? • Please provide a position statement for each GP practice in your health board area which is currently experiencing recruitment difficulties. For example, how many vacancies are there at each of these practices, how long has the recruitment process been underway, what impact has this had on the services available to patients?
Date of Response: 29/07/2025
View Response: 10298.pdf
Freedom of Information Request Reference: 10297
Date Received: 04/07/2025
Summary:
1) The total number of patients seen by the Caring for Smiles scheme in 2020, 2021, 2022, 2023 and 2024. 2) The cost to operate the Caring for Smiles scheme in 2020, 2021, 2022, 2023 and 2024.
Date of Response: 30/07/2025
View Response: 10297.pdf
Freedom of Information Request Reference: 10296
Date Received: 04/07/2025
Summary:
1) The total number of patients seen by the Open Wide scheme in 2020, 2021, 2022, 2023 and 2024. 2) The cost to operate the Open Wide scheme in 2020, 2021, 2022, 2023 and 2024.
Date of Response: 30/07/2025
View Response: 10296.pdf
Freedom of Information Request Reference: 10295
Date Received: 04/07/2025
Summary:
1) The total number of mobile dental units currently operated by the Health Board in 2025. 2) The total number of patients seen by the mobile dental units in 2020, 2021, 2022, 2023 and 2024. 3) The cost to operate the mobile dental unit service in 2020, 2021, 2022, 2023 and 2024.
Date of Response: 30/07/2025
View Response: 10295.pdf
Freedom of Information Request Reference: 10294
Date Received: 04/07/2025
Summary:
1) What is the projected annual cost saving generated by scrapping the Child Smile Infants' Tooth Brushing scheme specifically, not generally, in Our Lady of Lourdes Primary school on 18th June 2025? (Brushes, toothpaste and man-hours for administering the annual set-up). In summary: what was the cost of running the scheme before, and what is the predicted cost of running the scheme now that Our Lady of Lourdes is no longer included? 2) What other schools are affected by this cut in service? 3) In percentage terms, what is the trend of recorded tooth decay observed in pupils in Our Lady of Lourdes over the past five years?
Date of Response: 30/07/2025
View Response: 10294.pdf
Freedom of Information Request Reference: 10293
Date Received: 03/07/2025
Summary:
1. How many people were admitted to hospital in Lothianin last year (2024 calendar year) where obesity was the main reason for admission? 2. If possible, could you also provide this broken down by age?
Date of Response: 18/07/2025
View Response: 10293.pdf
Freedom of Information Request Reference: 10292
Date Received: 03/07/2025
Summary:
In the period 1st April 2025 to 30th June 2025 please provide a breakdown of: • Total trust spend with framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st April 2025 to 30th June 2025 please provide a breakdown of: • Total trust spend with off framework agencies for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name In the period 1st April 2025 to 30th June 2025 please provide a breakdown of: • Total trust spend with the internal trust bank or associated external provider for locum nurses Please provide a further breakdown for locum nurses by: • Spend per band • Spend per specialty • Spend per agency name Please confirm the total number of nursing shifts booked during this period for all agency nursing only, no bank staff nursing to be included (1st April 2025 to 30th June 2025) Please confirm the total number of nursing shifts booked above NHSE capped rates during this period for all agency nursing only, no bank staff nursing to be included (1st April 2025 to 30th June 2025)
Date of Response: 16/07/2025
View Response: 10292.pdf
Freedom of Information Request Reference: 10291
Date Received: 03/07/2025
Summary:
What is the content of any policy document or clinical referral protocol or guidance (henceforth abbreviated as ‘policy’) in current use in the Health Board which describes whether patients living with overweight or obesity, who are under consideration or seeking referral for hip or knee replacement surgery, are subject to any of the following: • A BMI threshold for referral to surgery or listing for surgery • A requirement to accept referral or support for weight management ahead of surgical referral or listing for surgery • A requirement to demonstrate attempted or successful weight loss ahead of surgical referral or listing for surgery • Postponement or delay to their surgical referral or listing for surgery, whether or not the patient chooses to engage in weight management during that time. What was the start date for the policy? What is the planned review date for the policy? If no such policy is currently in place, are there plans for policy introduction? If so, when and of what content?
Date of Response: 18/07/2025
View Response: 10291.pdf
Freedom of Information Request Reference: 10290
Date Received: 02/07/2025
Summary:
Q1. In the last 6 months, how many patients have been diagnosed with Diffuse Large B Cell Lymphoma (DLBCL)? Q1a. Of these patients, how many commenced treatment at your trust within the last 6 months? Q2. In the last 6 months, how many patients have you treated for Diffuse Large B Cell Lymphoma (DLBCL) with the following treatments: • R-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • R-mini-CHOP (rituximab, cyclophosphamide, doxorubicin hydrochloride, vincristine and prednisolone) • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • Pola-R-CHP (Polatuzumab vedotin with rituximab, cyclophosphamide, doxorubicin hydrochloride, and prednisolone) • R-CODOX-M (rituximab, cyclophosphamide, vincristine, doxorubicin and methotrexate) • R-IVAC (rituximab, ifosfamide, etoposide and cytarabine) • R-GCVP (Rituximab, gemcitabine, cyclophosphamide, vincristine, prednisolone) • (DA)-EPOCH +/-R (Prednisolone, doxorubicin, vincristine, etoposide, cyclophosphamide, rituximab) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Axicabtagene ciloleucel • Tisagenlecleucel • Epcoritamab • Loncastuximab tesirine • Glofitamab • Any other SACT • Stem cell transplant or bone marrow transplant (autologous or allogeneic) Q3. In the last 6 months, how many patients have received the following 2nd line treatments for Diffuse Large B Cell Lymphoma (DLBCL): • Axicabtagene ciloleucel (Yescarta) • Tisagenlecleucel • Pola-BR (polatuzumab vedotin with rituximab and bendamustine) • R-GemOX (rituximab, gemcitabine and oxaliplatin) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatments Q4. In the last 6 months, how many patients has the Trust treated for 3rd line Diffuse Large B Cell Lymphoma (BLBCL)? Q5. In the last 6 months, how many patients have you referred to other trusts for the treatment of Diffuse Large B Cell Lymphoma (DLBCL) for the following treatments: • CAR-T Therapy (E.g. Axicabtagene ciloleucel) • Stem cell transplant or bone marrow transplant (autologous or allogeneic) • Any other treatment
Date of Response: 31/07/2025
View Response: 10290.pdf
Freedom of Information Request Reference: 10289
Date Received: 02/07/2025
Summary:
1. Contract details a. Dates of commencement and expiry (including any extensions) of any contract(s) between NHS Lothian and MD Consents Ltd (or related entities). b. Contract duration and renewal terms. c. Total amounts paid (or projected to be paid) under these agreements to date. 2. Data retention and disposal a. Copies of the retention schedule/policy applicable to data collected via MD Consents. b. Retention durations for specific data types (e.g. consent forms, audit logs). c. Procedures for secure deletion or archiving once retention periods have lapsed. 3. Information governance / risk assessments a. Copies of any Data Protection Impact Assessments (DPIAs) or equivalent evaluations performed in relation to MD Consents. b. Records of any cyber/security risk assessments, vulnerability testing, or data-sharing reviews undertaken. c. Any formal Caldicott Guardian sign off or legal/IGD approvals related to deploying MD Consents.
Date of Response: 30/07/2025
View Response: 10289.pdf
Freedom of Information Request Reference: 10288
Date Received: 02/07/2025
Summary:
Information requested in respect of Peripherally Inserted Central Catheters (PICC): Volume inserted in calendar year 2024? What proportion are inserted: Under fluoroscopy? At the bed side? Other? Information requested in respect of Midline Catheters: Volume inserted in calendar year 2024? What proportion are inserted: Under fluoroscopy? At the bed side? Other?
Date of Response: 30/07/2025
View Response: 10288.pdf
Freedom of Information Request Reference: 10287
Date Received: 01/07/2025
Summary:
i) I would like to raise a Freedom of Information request to ascertain which GP practices within the NHS Lothian Health Board area have a Shared Care agreement with a private, non NHS organization allowing a patient to receive a diagnosis of ADHD from that private organization, and on which diagnosis the NHS would prescribe relevant ADHD medication to the patient. ii) I would also like to ask for a list of the private, non NHS, organizations GPs in NHS Lothian will accept a diagnosis of ADHD on behalf of a patient from and have a shared Care agreement for the purpose as described above.
Date of Response: 16/07/2025
View Response: 10287.pdf
Freedom of Information Request Reference: 10286
Date Received: 01/07/2025
Summary:
How many patients were treated in June 2025 (or latest available month) by the Dermatology department with the following drugs: •Abrocitinib (Cibinqo) •Baricitinib (Olumiant) •Dupilumab (Dupixent) •Lebrikizumab (Ebglyss) •Omalizumab (Xolair) •Tralokinumab (Adtralza) •Upadacitinib (Rinvoq) •Nemolizumab (Nemluvio) How many patients were treated in June 2025 (or latest available month) by the Respiratory Medicine departments with the following drugs: •Benralizumab (Fasenra) •Dupilumab (Dupixent) •Mepolizumab (Nucala) •Omalizumab (Xolair) •Reslizumab (Cinqaero) •Tezepelumab (Tezspire)
Date of Response: 16/07/2025
View Response: 10286.pdf
Freedom of Information Request Reference: 10285
Date Received: 01/07/2025
Summary:
My request concerns treatment approaches for inflammory arthritis. I wish to know what options for combination therapy are available in rheumatology for inflammatory arthritis. Specifically, I wish to know what options are available for combining multiple biologic (e.g. monoclonal antibodies) and/or small molecule (e.g. JAK inhibitors) treatments of inflammory arthritis. I am NOT interested in what combinations options are available for methrotrexate, leflunomide, or sulfasalazine. I would like to know what the process is for approving biologic and/or small molecule combination therapies, novel or otherwise.
Date of Response: 29/07/2025
View Response: 10285.pdf
Freedom of Information Request Reference: 10284
Date Received: 30/06/2025
Summary:
I would like to request information relating to all contracts between health boards in Scotland and the telecommunications firm Oricom Ltd. Now that the NHS Counter fraud services investigation into the company and the subsequent criminal trial has concluded, I wish to obtain the details of - - All contracts for services awarded to Oricom Ltd by Scottish health boards. - The value and length of these contracts and what they were for - Details of any contracts with Oricom terminated during the investigation into the company
Date of Response: 29/07/2025
View Response: 10284.pdf
Freedom of Information Request Reference: 10283
Date Received: 30/06/2025
Summary:
I wish to make a Freedom of Information Request for the number in patient beds the entire organisation had in 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023, 2024 & 2025 on the 1st of April of each year. With a breakdown of each year.
Date of Response: 08/07/2025
View Response: 10283.pdf
Freedom of Information Request Reference: 10282
Date Received: 20/06/2025
Summary:
Review request in relation to job evaluation.
Date of Response: 11/07/2025
View Response: 10282.pdf
Freedom of Information Request Reference: 10281
Date Received: 30/06/2025
Summary:
1. How many NHS staff members have been absent (headcount) with anxiety, stress, depression or other mental illness (ASDOM – NHS Scotland defined list), recorded as sickness absence’ in each year since 2020-21, including the current year to date? This would be any breaks from service not included in annual leave, due to high levels of stress. 2. What was the combined number of working days lost due to ASDOM in each year since 2020-21, including the current year to date.
Date of Response: 17/07/2025
View Response: 10281.pdf
Freedom of Information Request Reference: 10280
Date Received: 30/06/2025
Summary:
1. Prescription of Neurotoxins: o Does the Trust prescribe neurotoxins for patient treatment? (Yes/No) 2. Types of Neurotoxins Prescribed: o If yes, which neurotoxins are currently prescribed? (Please indicate all that apply)  Botox  Dysport  Xeomin  Myobloc  Other (please specify): 3. Departments Prescribing Neurotoxins: o Which departments or clinics within the Trust prescribe neurotoxins? (Please indicate all that apply or add any others)  Neurology  Urology  Dermatology  Rehabilitation Medicine  Pain Management / Anaesthetics  Ophthalmology  Gastroenterology  Maxillofacial Surgery/Dentistry  General Surgery/Orthopaedics  Other (please specify): 4. Patient Treatment Data: o Please provide the number of patients treated with each neurotoxin in the last 12 months?  Botox:  Dysport:  Xeomin:  Myobloc:  Other (please specify): 5. Departmental Breakdown: o Please break this down by department:  Neurology  Urology  Dermatology  Rehabilitation Medicine  Pain Management / Anaesthetics  Ophthalmology  Gastroenterology  Maxillofacial Surgery/Dentistry  General Surgery/Orthopaedics  Other (please specify): 6. Private Patient Treatments: o Number of private patients treated within the Trust with neurotoxins: o Number of private migraine patients treated with neurotoxins 7. Outsourcing of Neurotoxin Injections: o Does the Trust outsource neurotoxin injections to another provider, or are all injections performed in-house? If outsourced, which provider is used?
Date of Response: 28/07/2025
View Response: 10280.pdf
Freedom of Information Request Reference: 10278
Date Received: 27/06/2025
Summary:
I am trying to collate doctors' emails for our pharmacies and to try and help our IPs to get quicker access to the doctors' surgeries we use.
Date of Response: 16/07/2025
View Response: 10278.pdf
Freedom of Information Request Reference: 10277
Date Received: 27/06/2025
Summary:
I would like to request information about the admission of patients to the Orchard Clinic, in the Royal Edinburgh Hospital. I would like to know how many patients have been admitted and how many patients have been transferred out from the wards in the Orchard Clinic named Cedar and Hawthorn Wards from 17th March 2025 until June 26th 2025.
Date of Response: 17/07/2025
View Response: 10277.pdf
Freedom of Information Request Reference: 10276
Date Received: 27/06/2025
Summary:
The orthographic waiting list in Lothian is closed to new entrants until March 2026. I understand this decision was made by the NHS Lothian Corporate Management team. This is a Freedom of Information request: I want to see a copy of the paper that formed the basis for that decision, and also copies of all supporting documents. For the avoidance of doubt, that includes relevant Corporate Management team minutes, and all other papers, whether electronic or paper, including emails, meeting notes, memoranda and the like.
Date of Response: 31/07/2025
View Response: 10276.pdf
Freedom of Information Request Reference: 10269
Date Received: 25/06/2025
Summary:
Please may you provide me with: • The total number of cath labs in your Health Board • The number of cath labs are in each Trust • The age of each cath lab • Any plans to refurbish any of these cath labs • The volumes of private cardiology activity done in these NHS cath labs • Any trusts within the Health Board considering procuring managed cardiology services • Volume of NHS Cath lab and Outpatient Cardiology Activity last three years, broken by HRG code • Volume of Private Activity last three years, broken by CSSD code • Revenue of total NHS cath lab activity, last three years • Revenue of total Private cath lab activity, last three years • Private pricing schedules for all private cardiology activity, cath lab and outpatients • Profit & Loss last three years for private cath lab activity • Waiting list time by HRG code for cath lab procedure as of 1st June 2025 • Waiting list time for New Patient Consultation as of 1st June 2025 • Waiting list time for Cardiac CT as of 1st June 2025 • Waiting list time for Cardiac MRI as of 1st June 2025 • Waiting list time for Transthoracic Echo as of 1st June 2025 • Waiting list time for ambulatory monitor fitting as of 1st June 2025 • 12 month and 24 month re-do rate of Atrial Fibrillation procedures • 12, 24 and 36 month Morbidity and Mortality rate for PCI • Residual book value of all cardiac assets in current inventory • Any Outsourced work to IS providers and if so, the volumes of activity you outsource, and the revenue values of outsourced activity, on a line-by-line basis • Are you interested to explore a managed clinical services solution in your Health Board to support the potential reclaim of VAT on your consumables and/or the opportunity to release working capital through a ‘sale and leaseback’ (technology transfer agreement) of equipment and assets? • Are you interested to explore a ‘cardiology movement hub’, namely an IS provider developing an elective cardiology hub to provide cath lab procedures allowing the acute Trust in your Health Board to concentrate on emergency and more complex activity to remove scheduling conflicts and so reduce waiting times?
Date of Response: 15/08/2025
View Response: 10269.pdf
Carer Positive Icon
Awards Aware Icon
We are a Living wage Employer Icon
Duke of Edinburgh's Award Logo
Young Person's Guaranteed Employer Logo
Scottish Top Employers Logo
Disability Confident Employer Logo
 
CONTACT NHS LOTHIAN
Lothian NHS Board
Mainpoint
102 Westport
Edinburgh
EH3 9DN

Main Switchboard: 0131 242 1000
YOUR RIGHTS
OUR VALUES INTO ACTION
Around 3,000 colleagues across NHS Lothian have developed Our Values, a set of common values and ways of working - to the benefit of everyone working in the organisation and, most importantly - to the benefit of our patients.
WORKING WITH NHS LOTHIAN
MEDIA ENQUIRIES
STAY CONNECTED TO NHS LOTHIAN
Facebook
Twitter
YouTube
Vimeo
Instagram
PARTNERS